低危前列腺癌主动监测策略的成本效果分析
该研究采用状态转移马尔可夫模型,模拟50岁新诊断低危前列腺癌男性的自然病史,比较立即治疗、观察等待及不同主动监测(AS)随访方案的成本与效果。结果显示,基于MRI每5年随访一次较观察等待可提高质量调整生存4.47个质量调整月,且按Medicare报销费率具有高价值;更频繁的MRI随访ICER超过每QALY 80万美元,不符合成本效果标准。穿刺活检策略在各随访间隔下均较对应MRI策略效果更差且成本更低。
要点
- 基于MRI每5年随访一次较观察等待可提高4.47个质量调整月,按Medicare费率具有成本效果。
- 更频繁的MRI随访ICER超过每QALY 80万美元,不符合标准成本效果阈值。
- 穿刺活检策略在各随访间隔下均较对应MRI策略效果更差且成本更低。
核心结论
- 在Medicare报销费率下,将MRI纳入主动监测方案并降低重复检测强度,对于选择保守管理的低危前列腺癌男性可能具有成本效果。
研究设计与样本
- 采用状态转移马尔可夫模型,模拟50岁新诊断低危前列腺癌假设队列的自然病史(即不检测或不干预)。
- 诊断后假设男性接受立即治疗、观察等待或多种主动监测策略之一。
- 主动监测随访采用经直肠超声引导穿刺活检或MRI,按每年、每2年、每3年、PRIAS方案(第1、4、7、10年,之后每5年)或每5年进行。
- 主动监测期间诊断出更高分级或分期疾病则接受治愈性治疗。
主要发现
- 与观察等待相比,基于MRI每5年随访一次提高质量调整生存4.47个质量调整月,按Medicare报销费率使用标准成本效果指标属于高价值医疗。
- 对于每个检测间隔,基于活检的策略均较对应的基于MRI的策略效果更差且成本更低。
- 更频繁间隔的基于MRI监测ICER大于每QALY 80万美元,按标准指标不认为具有成本效果。
- 结果对两种活检模式检测临床显著癌的诊断准确性和成本敏感。
关键数值与推荐
- 结果指标包括贴现质量调整生命年(QALY)、贴现终身医疗成本(2017年美元)和增量成本效果比(ICER)。
- 基于MRI每5年随访一次较观察等待提高4.47个质量调整月,按Medicare报销费率具有高价值。
- 更频繁MRI随访的ICER大于每QALY 80万美元,不符合标准成本效果。
临床怎么用
- 对于选择保守管理的低危前列腺癌男性,可考虑将MRI纳入主动监测方案并降低重复检测强度,但需结合MRI成本判断成本效果。
- 穿刺活检策略虽成本更低但效果更差,选择时需权衡诊断准确性与成本。
局限性
- 结果为模型模拟,基于假设队列和参数,对外部真实世界数据的普适性需进一步验证。
- 结果对两种活检模式检测临床显著癌的诊断准确性和成本敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) has become the recommended management strategy for men with low-risk prostate cancer. However, there is considerable uncertainty about the optimal follow-up schedule in terms of the tests to perform and their frequency. OBJECTIVE: To assess the costs and benefits of different AS follow-up strategies compared to watchful waiting (WW) or immediate treatment. DESIGN, SETTING, AND PARTICIPANTS: A state-transition Markov model was developed to simulate the natural history (ie, no testing or intervention) of prostate cancer for a hypothetical cohort of 50-yr-old men newly diagnosed with low-risk prostate cancer. Following diagnosis, men were hypothetically managed with immediate treatment, watchful waiting, or one of several AS strategies. AS follow-up was performed either with transrectal ultrasound-guided biopsy or magnetic resonance imaging (MRI) which was scheduled annually, biennially, every 3yrs, according to the PRIAS protocol (yrs 1, 4, 7, and 10, and then every 5yr) or every 5yr. Diagnosis of higher-grade or -stage disease while on AS resulted in curative treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured discounted quality-adjusted life years (QALYs), discounted lifetime medical costs (2017 US$), and incremental cost-effectiveness ratios (ICERs). RESULTS AND LIMITATIONS: Compared to WW, MRI-based surveillance performed every 5yr improved quality-adjusted survival by 4.47 quality-adjusted months and represented high-value health care at the Medicare reimbursement rate using standard cost-effectiveness metrics. Biopsy-based strategies were less effective and less costly than the corresponding MRI-based strategies for each testing interval. MRI-based surveillance at more frequent intervals had ICERs greater than $800000 per QALY and would not be considered cost-effective according to standard metrics. Our results were sensitive to the diagnostic accuracy and costs of both biopsy modes in detecting clinically significant cancer. CONCLUSIONS: Incorporation of MRI into surveillance protocols at Medicare reimbursement rates and decreasing the intensity of repeat testing may be cost-effective options for men opting for conservative management of low-risk prostate cancer. PATIENT SUMMARY: Our study modeled outcomes for men with low-risk prostate cancer undergoing watchful waiting, immediate treatment, or active surveillance with different follow-up schedules. We found that conservative management of low-risk disease optimizes health outcomes and costs. Furthermore, we showed that decreasing the intensity of active surveillance follow-up and incorporating magnetic resonance imaging (MRI) into surveillance protocols can be cost-effective, depending on the MRI costs.
引用
- Sathianathen NJ, Konety BR, Alarid-Escudero F, et al. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. 2018. PMID: 30425010. doi:10.1016/j.eururo.2018.10.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。